Lixisenatide
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 696 publications
Editorial Expression of Concern: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
Journal: BMC neuroscience
Published: October 30, 2026
Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.
Journal: BMJ open
Published: October 01, 2026
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.
Journal: Heart rhythm
Published: September 22, 2026
Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.
Journal: Foot & ankle specialist
Published: August 18, 2026
Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
Journal: Clinics in dermatology
Published: August 14, 2026
Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: July 30, 2026
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
Journal: Pharmacological research
Published: July 27, 2026
Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data.
Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Published: July 14, 2026
Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate glucagon-like protein-1 receptor agonist (GLP-1RA) carcinogenicity risk.
Journal: Regulatory toxicology and pharmacology : RTP
Published: July 14, 2026
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
Journal: Diabetes, obesity & metabolism
Published: July 14, 2026
Patient-Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative Review.
Journal: Diabetes, obesity & metabolism
Published: July 07, 2026
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Journal: Annals of internal medicine
Published: June 15, 2026
Last Updated: 11/08/2026